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RhoB is an early-response gene whose expression is
elevated by multiple cellular stresses; this gene plays
an important role in cancer, macrophage motility,
and apoptosis. These factors are essential for the on-
set of type 1 diabetes mellitus and related complica-
tions. This study explores the role of RhoB in -cell
depletion and hyperglycemia-associated complica-
tions and tests whether the pleiotropic effect of st-
atins on glycemic control is RhoB dependent. We in-
duced -cell depletion in RhoB/, RhoB/, and
RhoB/mice with streptozotocin (STZ). Diabetic sta-
tus was assessed by glucose tolerance and pancreatic
islet loss. RhoB/ mice showed a significant reduc-
tion in the severity of STZ-induced diabetes; only 13%
of the STZ-treated RhoB-null animals became hyper-
glycemic, as opposed to 61% of the wild-type controls.
Diabetes-related complications, such as wound heal-
ing rate and onset of nephropathy, were also as-
sessed. Hyperglycemic RhoB/mice had fewer signs
of nephropathy and showed faster wound healing
than RhoB/ animals. After assessing the diabetic sta-
tus of mice treated simultaneously with STZ and simva-
statin, we conclude that the effect of statins in improv-
ing glycemic control is RhoB independent. We propose
that RhoB is a modifier of diabetes, important for the
induction of -cell loss. Suppression of RhoB expres-
sion may have potential application in the treatment of
diabetes and associated complications. (Am J Pathol
2011, 178:245–252; DOI: 10.1016/j.ajpath.2010.11.040)RhoB is an early-response gene whose expression is
elevated by cellular stresses, including UV irradiation and
hypoxia.1 The RhoB gene encodes a small GTPase that
regulates vascular sprouting and intracellular trafficking
of v-akt murine thymoma viral oncogene homolog 1 (AKT)
in endothelial cells.2 This protein has also been impli-
cated in a variety of cellular processes, such as migration
and adhesion in macrophages, endocytosis, epidermal
growth factor signaling, actin organization, intracellular
trafficking, and DNA damage–induced apoptosis.1,3–7 All
of these are important processes for type 1 diabetes
mellitus onset and for the complications associated with
hyperglycemia, such as delayed wound healing and ne-
phropathy. However, to our knowledge, RhoB has not
been examined in the context of diabetes and hypergly-
cemia.
Rho GTPases can be found in two forms: the active
GTP-bound form, generated by guanine nucleotide ex-
change factors; and the inactive form, bound to GDP by
the GTPase-activating proteins. Both can be post-trans-
lationally modified by cysteine prenylation. Although
RhoB can be prenylated by either a farnesyl group or a
geranylgeranyl group, RhoA and RhoC can only be gera-
nylgeranylated. The method of prenylation of the Rho
GTPases determines its cellular localization.8,9
Statins have been shown in previous studies9,10 to
prevent hyperglycemia in nonobese diabetic mice and
streptozotocin (STZ)–treated mice. The mechanism by
which this is achieved is still unclear. Statins are HMG-
CoA reductase inhibitors broadly used to control choles-
terol levels and mitigate cardiovascular disease. This in-
hibition affects the mevalonate pathway, inhibiting Rho
prenylation by preventing the formation of farnesyl and
geranylgeranyl isoprenoids. We tested the effect of the
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AJP January 2011, Vol. 178, No. 1drug simvastatin in STZ-induced hyperglycemia in
RhoB/, RhoB/, and RhoB/mice to assess whether
the effect of simvastatin was linked to RhoB.
Materials and Methods
Animals
RhoB/, RhoB/, and RhoB/ mice were kept in 12-
hour night/day light cycles and fed at libitum. Equal num-
bers of female and male animals were used. Mice were
aged 4 to 6 weeks. The Beth Israel Deaconess Medical
Center Institutional Animal Care and Use Committee ap-
proved all animal protocols used in this study. The Prin-
ciples of Laboratory Animal Care (National Institutes of
Health publication 85-23, rev 1985) were followed.
Multiple Low-Dose STZ Treatment
Diabetes was induced in 8- to 10-week-old Balb/cJ,
C57Bl/6J, RhoB/, RhoB/, and RhoB/ mice by i.p.
injection of STZ at 40 mg/kg in 10-mmol/L citrate buffer
(pH 4.6) for five consecutive days. Animals fasted for 4
hours before each injection. Citrate buffer was injected as
a control arm of the experiments. At 30 days after the STZ
injection, diabetes was confirmed by blood glucose mea-
surement using a blood glucose monitoring system (One
Touch; Lifescan, Milpitas, NV). Animals were considered
hyperglycemic when, after fasting for 4 hours, blood glu-
cose levels were greater than 250 mg/dL.
Mice Islets Study
Islets from five STZ-treated and untreated mice were
extracted using collagenase treatment, followed by the
gradient centrifugation method.11 Real-time PCR was
performed on them as described later.
Wound Healing Assay
Animals that had been hyperglycemic for 4 weeks were
anesthetized with isoflurane; then, an 8-mm diameter skin
punch was performed on the dorsal surface of the body.
Every 2 days, pictures of the wound area were taken and
the area of the wound was calculated.
Nephropathic Analysis
Kidneys were examined from animals that had been
hyperglycemic for 3 to 4 months. Renal slices were
fixed in 4% paraformaldehyde, embedded in paraffin,
and deparaffinized in xylene. Then, 4-m sections were
stained with hematoxylin-eosin, PAS, and Masson
trichrome. The extent of renal injury was assessed by
morphometric analysis of the glomerular disease and
interstitial fibrosis, as previously described.12 For glomer-
ular damage, we evaluated mesangial expansion and
enlargement of the glomeruli. A point counting method
was used to quantify the mesangial matrix deposition
according to a previous method, with some modifica-tions.13 We analyzed 20 PAS-stained glomeruli from each
mouse on a digital microscope screen grid containing
667 (29  23) points. To obtain the percentage of mes-
angial matrix deposition (mesangial matrix index) in a
given glomerulus, the number of grid points that land on
a pink or red mesangial matrix deposition was divided by
the total number of points in the glomerulus. The relative
interstitial volume was evaluated by morphometric anal-
ysis using a 10-m graticule fitted into the eyepiece of the
microscope. We evaluated 10 randomly selected cortical
areas under 200 magnification for each mouse.
Immunostaining
For insulin and glucagon labeling, 10- to 15-m sections
were prepared as previously described. Sections were
blocked with 3% normal donkey serum for 30 minutes at
room temperature and incubated at 4°C overnight with
nonimmune serum, followed by a rabbit antiserum raised
against glucagon (Linco Research Inc, St Charles, MO)
at a dilution of 1:3000. After rinsing with PBS, slides were
blocked again with 3% donkey serum for 10 minutes at
room temperature and then localized with donkey anti–
rabbit-conjugated biotin (Jackson ImmunoResearch Lab-
oratories Inc, West Grove, PA) (1:500) for 1 hour at room
temperature. Slides were then washed twice in PBS and
incubated in conjugated antibody (Alexa Fluorescent;
Molecular Probes, Eugene, OR; diluted 1:400 in PBS) for
1 hour at 37°C. Finally, slides were incubated in guinea
pig anti–bovine insulin serum (1:200; Linco Research
Inc) and localized with anti–guinea pig antibody (1:200)
(Texas Red) for 1.5 hours at room temperature. Slides
were mounted with fluorescent mounting medium (Vector
Laboratories Inc, Burlingame, CA) and stored in the dark.
Glucose Challenge
After animals had fasted for 4 hours, their basal glucose
level was measured using a blood glucose monitoring
system (One Touch). They were then injected i.p. with
10-L/g body weight of 10-mg/ml D-glucose in PBS.
Blood glucose levels were measured at 15, 30, 60, and
120 minutes after injection.
Pancreatic Analysis
Pancreas specimens were surgically removed, fixed in
4% paraformaldehyde for 2 hours, and then placed in
30% sucrose and frozen in OCT. Sections of 10 m were
cut and placed in slides. Five nonconsecutive slides per
animal were labeled for insulin and glucagon. The num-
ber of islets was then counted, and pictures were ob-
tained. The location of -cell apoptosis was identified
using dual immunofluorescence for terminal deoxynu-
cleotidyl transferase–mediated dUTP nick-end labeling
(TUNEL) and insulin staining. We used a labeling
(TUNEL) kit (Roche; Molecular Biochemicals, Indianapo-
lis, IN) with a modified protocol for immunofluores-
cence. The sections were examined using confocal
microscopy. The TUNEL-positive  cells were identi-
fied by the presence of red nuclei and green cyto-
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software (ImageJ).
Statins and STZ
A total of 12 RhoB/, 21 RhoB/, and 34 RhoB/ 8- to
10-week-old male and female mice were used for these
experiments. The mice were divided into two treatment
groups: one was treated with saline vehicle and multiple
low-dose STZ treatment (MLDS), and the other was
treated with simvastatin and MLDS. Simvastatin was dis-
solved in 100 L of ethanol and 150 L of 0.1 N sodium
hydroxide, incubated at 50°C for 2 hours, pH adjusted to
7.0, and volume corrected to 1 ml. Once a day, for five
consecutive days, the mice received an i.p. injection of
either saline (0.2 ml) or freshly prepared STZ, as previously
described. Two days before the STZ injections started and
for 12 consecutive days, the mice received a daily i.p.
injection of either vehicle (0.2 ml) or simvastatin (30-mg/kg
body weight; 0.2 ml) dissolved in vehicle. When required,
the STZ/saline injections were administered 30 minutes be-
fore the simvastatin/vehicle injections.
Statistical Analysis
Values are the mean  SEM. The significance of the
differences between the two groups was analyzed by the
Student’s t-test. Comparisons among three groups were
performed by two-way analysis of variance, followed by
Scheffé’s test to evaluate the significance of the differ-
ences between any two groups. P  0.05 was defined as
statistically significant.
Real-Time RT-PCR Analysis
RNA was extracted using reagent (Trizol; Invitrogen, Carls-
bad, CA) following the manufacturer’s instructions. All sam-
ples were treated with DNase I to prevent genomic DNA
contamination. Reverse transcription was performed using
a cDNA reverse transcription kit following the manufactur-
er’s instructions (Applied Biosystems, Foster City, CA). The
cDNA generated was stored at 80°C until required for
quantification. An RT-PCR machine (ABI Prism 7000 Se-
quence Detection System; PE Applied Biosystems) was
used to amplify cDNA and detect PCR amplicons using
the following sequence-specific primers for glyceralde-
hyde-3-phosphate dehydrogenase (forward, 5=-AACTTT-
GGCATTGTGGAAGGGCTC-3=; reverse, 5=-TGGAA-
GAGTGGGAGTTGCTGTTGA-3=) and RhoB (forward,
5=-GCATCAACTGCTGCAAGGTGCTAT-3=; reverse, 5=-
TAATTCTCAGCGTGACCAGCCAGA-3=). Because the
RhoB gene contains no introns, tubes were added on
every run containing RNA instead of cDNA. No significant
genomic contamination was detected. PCR reactions
were performed in 96-well optical reaction plates (PE
Applied Biosystems). Quantitative real-time PCR was nor-
malized to the copies of glyceraldehyde-3-phosphate de-
hydrogenase mRNA from the same sample. To compare
relative levels of mRNAs and to reduce experimental
error, from plate to plate, expression levels were com-pared with those of one sample that was run on every
plate and used as an internal control. Results were given
as relative quantization to one sample based on the fol-
lowing equation: FC  2dCT, with dCT (CT) calcu-
lated as the difference in CT values between the gene of
interest and glyceraldehyde-3-phosphate dehydroge-
nase. Acquired data were analyzed by software (Se-
quence Detector Software; PE Applied Biosystems).
For all assays, controls and samples were analyzed in
triplicate in a final reaction volume of 20 L. PCR ampli-
fication included an initial phase of 2 minutes at 50°C,
followed by 10 minutes at 95°C, and 40 cycles of 15
seconds at 95°C and 1 minute at 60°C.
In Vitro Studies
Mouse insulinoma TC3 cells were used for these stud-
ies. Cells were cultured in Dulbecco’s modified Eagle’s
medium containing 25-mmol/L glucose supplemented
with 10% fetal bovine serum, 100-IU/ml penicillin, 100-
IU/ml streptomycin, and 2-mmol/L L-glutamine under
95% oxygen plus 5% carbon dioxide. The medium was
changed twice a week, and cells were trypsinized and
subcloned weekly. Cells were used between passages
20 and 65. The short hairpin (sh) RNAs for target genes
used in this study were constructed in pLKO.1-puro
vector (The RNAi Consortium at Broad Institute, Cam-
bridge, MA). A plasmid carrying a nontargeting se-
quence was used to create the control cells. Lentiviral
packaging and infection of the target cells were per-
formed according to the The RNAi Consortium proto-
col, with some modifications. For virus packaging, 2.1
g of the hairpin-pLKO.1 empty vector or vector con-
taining the target gene-specific shRNA constructs was
cotransfected with 3.7 g of lentiviral packaging plas-
mid pCMVdR8.7psPAX2 containing gag, pol, and rev
genes and 0.2 g of envelope plasmid VSV-G into
293T cells. All plasmids were added to 400 L of
serum-free Dulbecco’s modified Eagle’s medium and
18 L of polyethylenimine (1 mg/ml) (Polysciences,
Inc, Warrington, PA). The mixture was vortex mixed for
10 seconds at high speed and incubated at room tem-
perature for 15 minutes. The 293T cells were
trypsinized. Then, the DNA mix was added to 3.5  106
293T cells. Forty-eight hours after transfection, the vi-
rus-containing media were collected, filtered, and
added to trypsinized TC3 cells in the presence of
hexadimetherine bromide, 95% or greater (polybrene,
8 g/ml) (Sigma-Aldrich, St. Louis, MO) for 24 hours.
The infected cells were then subjected to selection with
puromycin (Sigma-Aldrich) (2 g/ml). For the cell pro-
liferation study, plates were analyzed after 24, 48, 72,
and 96 hours with cell proliferation reagent (WST-1;
Roche Molecular Biochemicals) according to the man-
ufacturer’s instructions. For the STZ toxicity test, cells
were either treated with media or STZ (5 mmol/L) for 6
hours. Viability was calculated by trypan blue dye ex-
clusion.
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Hyperglycemia Induces RhoB Expression
The MLDS treatment used in our studies is one of the most
common methods of inducing a type 1 diabetes–like patho-
logical feature in vivo.14 The STZ is a nitrosourea compound
that enters the  cell through a specific low-affinity Glut-2
glucose transporter; it causes massive methylation of the
Figure 1. Expression of RhoB is induced by hyperglycemia. A: In all three
tested strains of mice, the levels of RhoB protein in the kidney increased
significantly 2 months after STZ injection. B: Results of RhoB expression in
mouse pancreatic islets measured by RT-PCR before (white bar) and after
(black bar) 3 weeks of hyperglycemia. The expression of RhoB in purified
islets of RhoB/ mice is significantly higher than in those of normoglycemic
control mice. Values are mean  SE. The SE is shown as the error bar.
Normoglycemic, n  5; and hyperglycemic, n  5. *P  0.01 for normogly-
cemic versus hyperglycemic.DNA and proteins, collapsing the DNA repair mechanism
and leading to apoptosis and the subsequent attack of 
cells by T cells and macrophages.9,10,15 We used this treat-
ment with several different strains of mice (Balb/cJ, C57Bl/
6J, and RhoB/), waited for 6 weeks for hyperglycemia to
become well established, and measured RhoB expression
in the kidney by Western blot analysis (Figure 1A). The
results show an increase in RhoB protein levels in the dia-
betic kidney of each strain. We also used real-time RT-PCR
to check whether RhoB expression levels changed in pan-
creatic islets after STZ treatment. Our results show that
RhoB expression, in pancreatic islets of hyperglycemic
mice, significantly increases 3 weeks after the last STZ
injection when compared with those that only received the
vehicle (Figure 1B).
RhoB/ Animals Are Protected against
STZ-Induced Hyperglycemia
To study whether the association of RhoB expression
and diabetes had functional consequences, we in-
jected RhoB/, RhoB/, and RhoB/ control ani-
mals with STZ and measured the change in fasting
glucose levels and the number and size of the pancre-
atic islets with time (Figure 2). Although 61% of the
RhoB/ control animals became hyperglycemic (blood
Figure 2. RhoB/ animals are resistant to STZ-
induced diabetes. A: Incidence of hyperglyce-
mia in RhoB/ and RhoB/ mice. When
treated with multiple-dose STZ injections, after 4
weeks, only 13% of the RhoB/ animals be-
came hyperglycemic (left bar, black portion)
(glucose level 250 mg/dL), whereas in the
RhoB/ background control, 61% of the ani-
mals became hyperglycemic (right bar, black
portion). RhoB/, n  170; and RhoB/, n 
214. B: Fasting glucose levels in hyperglycemic
animals. In animals with a fasting glucose level
of greater than 250 mg/dL, the average glucose
level of the hyperglycemic RhoB/ animals
(black bars) was lower than in the RhoB/
animals (white bars). Both groups showed a
slow increase in their average fasting glucose
levels with time. Values are mean  SE. The SE
is shown as the error bar (d  5). RhoB/,
n  45; and RhoB/, n  92 (any other point).
RhoB/, n  14; and RhoB/, n  11. *P 
0.005 for RhoB/ versus RhoB/. C: Cell pro-
liferation study on mouse insulinoma TC3 cells.
We used short-hairpin RNA to knock down
RhoB in these cells. The solid line represents the
proliferation rate of cells in which RhoB had
been knocked down, whereas the dotted line
represents cells infected with empty vector.
Knocking down RhoB did not increase the pro-
liferation rate of the cells. Indeed, it significantly
slowed it down. *P  0.001 for RhoB shRNA
versus empty vector. D: Glucose tolerance test.
All RhoB/, RhoB/, and RhoB/ STZ-
treated animals showed poor glycemic control
after i.p. glucose injection (1 g/kg) (solid lines)
when compared with the vehicle-injected con-
trols (dashed lines). Still, glycemic control was
worse in animals with one or more copies of
RhoB. Values are mean SE. The SE is shown as
the error bar. RhoB/, n  6; RhoB/ , n  6;
RhoB/, n  5; STZ-RhoB/, n  15; STZ-
RhoB/, n  8; and STZ-RhoB/, n  21. *P
 0.01 for the STZ-injected versus the vehicle
group.
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only 13% of the RhoB/-treated animals became hyper-
glycemic (Figure 2A). Of those 13% of RhoB/ animals
that became diabetic, the level of hyperglycemia aver-
aged values of approximately 350 mg/dL; in the RhoB/
controls, the fasting glucose levels averaged 450 to 500
mg/dL (Figure 2B). In both mice strains, there is an initial
steep increase in fasting glucose levels 3 days after the
last STZ injection. This increase corresponds to the initial
wave of -cell death. After a short plateau, the fasting
glucose levels continued to increase in all hyperglycemic
mice 24 days after the last injection.
The  cells can multiply in certain situations.16,17 To test
whether  cells of RhoB-null animals are less sensitive to
STZ or maintained function by repopulating islets after initial
cell death, we knocked down RhoB in mouse insulinoma
TC3 cells and performed a cell proliferation study by ob-
serving them for 96 hours (Figure 2C). Our results show that
knocking down RhoB in TC3 cells does not increase the
proliferation rate of the TC3 cells and that it slows cell
proliferation down, suggesting that the improved blood glu-
cose levels are not because of -cell recovery.
We also assessed the ability of  cells to produce insulin
and mediate glucose intake after 4 weeks of STZ treatment
by performing a glucose tolerance test (Figure 2D). All phe-
notypes showed signs of defective insulin production and
delayed glucose uptake when compared with their non–
STZ-injected controls. RhoB expression correlated with
poor glycemic control during glucose challenge. Rather,
when we looked at the pancreas of these animals (Figure 3,
A–D), we found that 14 and 65 days after STZ injection,
there were significantly more islets in the RhoB-null animals’
pancreas than in the RhoB/ controls (Figure 3A), indicat-
ing that reduced islet damage may explain the better blood
glucose levels in the RhoB/ mice.
Fourteen days after the last STZ injection (Figure 3C),
there are few insulin-producing cells left in the RhoB/
mice and most of the cells remaining in the islets are
glucagon-producing  cells. We used double staining
with TUNEL and insulin to detect apoptosis and deter-
mine the rate of cell death after STZ injection (Figure 3, B
and D). Three days after STZ treatment, the RhoB/
mice showed five times more TUNEL-positive  cells than
the RhoB/ mice. The difference is still significant 14
days after treatment, with more TUNEL-positive nuclei in
the pancreatic islets of RhoB/ mice.
To determine that the cause of the resistance to the drug
of RhoB/ animals is indeed caused by different sensitivity
of their  cells and not different reasons, such as different
permeability of STZ, we performed an in vitro study using
TC3 cells. For this study, we checked the survival rate of
these cells to STZ after knocking down RhoB. We show that
RhoB can be efficiently knocked down in these cells (Figure
3E) and that reduction of RhoB expression significantly re-
duces the death rate caused by STZ in TC3 cells (Figure
3F). We concluded from these studies that RhoB functions
in hyperglycemic stress to exacerbate islet damage and
metabolic dysfunction. This could be related to the already
established function of RhoB in promoting DNA damage–
induced apoptosis; in this case, this occurs in the pancre-
atic islets after STZ exposure.Diabetic RhoB/ Animals Show Fewer Signs
of Nephropathy
In part because we had observed RhoB induction in the
kidney of diabetic mice (Figure 1A), and because we had
previously shown RhoB to be important for microvascular
function in other organs,2 we investigated whether RhoB
Figure 3. A: Effect of STZ on the number of pancreatic islets. In both strains,
the number of pancreatic islets decreased 4, 14, and 65 days after the last STZ
injection, but the number of islets is significantly higher in RhoB/ (black
bars) pancreas than in the RhoB/ (white bars) at days 14 and 65. Values
are mean  SE. The SE (n  5 to 8) is shown as the error bar. *P  0.05 for
RhoB/ versus RhoB/. B: Quantitative analysis of apoptotic  cells in the
pancreas after STZ treatment shows that 4 and 14 days after the last STZ
injection, RhoB/mice have significantly fewer TUNEL-positive  cells than
RhoB/ mice. Values are the mean  SE. The SE (n  5 to 8) is shown as
the error bar. *P  0.05 for RhoB/ versus RhoB/. C: Immunohistochem-
istry labeling of pancreatic  cells (insulin in green and glucagon in red). For
both, RhoB/ and RhoB/ show STZ-induced -cell depletion and de-
crease in size and number of pancreatic islets. Still, the effect is more dramatic
in RhoB/, in which, after 14 days of the last STZ injection, the ratio of
insulin-producing cells/glucagon-producing cells decreased significantly while
insulin-producing islets can still be found in RhoB/ sections. D: Immunohis-
tochemistry labeling of pancreatic  cells (insulin in green, TUNEL positive in
red, and nuclei in blue). E: RhoB expression measured by RT-PCR in mouse
insulinoma TC3 cells. The white bar is the expression of cells infected with
empty plasmid. The black bar represents RhoB expression after the cells have
been infected with shRNA to knock down RhoB. The expression level decreased
60%. Values are the mean  SE. The SE is shown as the error bar. PLK0, n  5;
and sh-RhoB, n  5. *P  0.01 for PLK0 versus sh-RhoB. F: Knocking down
RhoB in TC3 cells significantly reduced their sensitivity to STZ-induced cell
death. Values are the mean  SE. The SE is shown as the error bar. PLK0, n 
5; and sh-RhoB, n  5. *P  0.01 for PLK0 versus sh-RhoB.expression affected secondary damage from hypergly-
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a common complication of diabetes, characterized by
accumulation of extracellular matrix in the glomeruli. This
leads to thickening of the capillary and Bowman’s cap-
sule basement membrane and mesangium in the glomer-
ulus. The result is glomerulosclerosis and eventually pro-
teinuria and renal failure. Mice show early signs of
nephropathy in the mesangial matrix after 3 months of
becoming hyperglycemic, allowing us to observe early
onset of nephropathy in the diabetic animals. The STZ-
treated animals used in this experiment were diabetic for
at least 6 months before the analysis; and the fasting
blood glucose levels of RhoB/ and RhoB/mice were
matched as closely as possible, considering that in most
cases RhoB/ mice had significantly lower fasting glu-
cose levels than RhoB/ mice.
We looked at glomerular size and mesangial matrix
accumulation in STZ-treated and nontreated RhoB/
and RhoB/ controls (Figure 4). In both groups of STZ-
treated animals, there was a significant increase in ne-
phropathy compared with non–STZ-treated animals, rep-
resented by an increase of glomerular surface area
(Figure 4, A and B) and accumulation of mesangial matrix
(Figure 4, A and C) when compared with the non–STZ-
injected animals. When we examined the glomeruli, we
observed no difference between the RhoB/ and
RhoB/ control or the MLDS-treated groups (Figure 4B).
However, with a threefold increase in the RhoB/ strain
and a twofold increase in the RhoB/ animals, there was a
significant difference in themesangial matrix index between
the STZ-treated animals and their normoglycemic counter-
Figure 4. Hyperglycemic RhoB/ kidneys showed fewer signs of early
nephropathy compared with those of the wild-type control group. A: Hema-
toxylin-eosin staining of the glomeruli. Both diabetic groups (bottom) had
an enlarged glomerular surface area and accumulation of mesangial matrix
compared with the nondiabetic groups (top) at 6 months of diabetes dura-
tion. B: Glomerular size increases with hyperglycemia in both RhoB/
(white bars) and RhoB/ (black bars) groups. Values are the mean  SE.
The SE is shown as the error bar. RhoB/, n  79; RhoB/, n  60;
STZ-RhoB/, n 80; and STZ-RhoB/, n 60. *P 0.01 versus non-STZ.
C: The STZ-treated RhoB/ mice (black bar, right) showed less severe
mesangial matrix accumulation compared with diabetic RhoB/ (white bar,
right). Values are the mean  SE. The SE is shown as the error bar. #P  0.01
versus STZ RhoB/, and *P  0.01 versus non-STZ. RhoB/, n  79;
RhoB/, n  60; STZ-RhoB/, n  80; and STZ-RhoB/, n  60.parts. Still, the diabetic RhoB/ animals show significantlyless nephropathy than the diabetic wild-type mice (Figure
4C). RhoB/ mice showed significantly less matrix accu-
mulation around the capillaries of the glomeruli. In all, long-
term hyperglycemia in the absence of RhoB resulted in
reductions in kidney damage.
This result suggests that RhoB knockout inhibits the
accumulation of mesangial matrix without decreasing the
size of enlarged glomeruli in those with diabetes.
Diabetic RhoB/ Animals Show Fewer Signs
of Retarded Wound Healing
Because the STZ-treated hyperglycemic RhoB/ mice
showed fewer signs of nephropathy than the RhoB/
controls, we decided to assess another diabetic compli-
cation: delayed wound healing. Hyperglycemia induced
by STZ treatment of mice was previously reported to
cause delayed wound healing.18 The STZ and non–STZ-
treated RhoB/ and RhoB/ animals were wounded
with an 8-mm-diameter full-thickness dorsal skin punch.
No significant differences were observed comparing the
normoglycemic groups (RhoB/ versus RhoB/) (Fig-
ure 5, A–C). Yet, there was a significant difference in
STZ-treated animals of both groups (Figure 5, A–C). The
hyperglycemic RhoB/ animals experienced delayed
wound healing. Notably, after 14 days, they still had a large
wound area, with 30% of the initial punch still healing. On
the other hand, the RhoB/ animals showed little delay in
the healing process. In fact, the healing was similar to their
non–STZ-treated (nondiabetic) peers. Microscopic analysis
of the wounds (Figure 5, B and C) showed delayed healing
in the RhoB/ STZ-treated animals with abundant granu-
lating tissue, edema, and scabbing 14 days after wounding.
At the same point, the RhoB/ STZ-treated animals had
almost completely healed, showing less granulated tissue
around the site of the wound and overall better organization
of the epidermal layer.
Statin Amelioration of Hyperglycemia Further
Improves Outcome in RhoB-Null Mice
Statins ameliorate hyperglycemia in nonobese diabetic
and STZ-treated mice.9 Because RhoB becomes preny-
lated on cysteines and the prenylation pathways are
downstream of statins, we surmised that the pleiotropic
effect of statins on glycemic control might be a conse-
quence of the inhibition of RhoB prenylation. To test
whether those two events were related, we injected
RhoB/, RhoB/, and RhoB/ animals with simvasta-
tin for 14 days. On day 2 after the first simvastatin injec-
tion, some of the animals were also injected with low-
dose STZ. Simvastatin decreased the average fasting
blood glucose level (Figure 6, dashed lines), when com-
pared with animals that only received STZ treatment and
vehicle (Figure 6, solid lines), and also decreased the
percentage of animals developing diabetes in all groups.
These experiments showed that glycemic control levels
of RhoB and simvastatin are independent of each other
and can be an added benefit in fighting diabetes.
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The data we have collected provide strong evidence for
RhoB as a potential target to ameliorate diabetes by
improving glycemic control and reducing complications.
Extensive work1,2,4,19–23 has been performed in the can-
cer field on RhoB’s proapoptotic properties, its capacity
to regulate angiogenesis, and its role as a tumor sup-
pressor. RhoB is also important for intracellular transport,
actin regulation, macrophage motility, and activation.3
Perhaps what is common in these various roles of RhoB is
that they all reflect functions for RhoB in pathological
settings or states of cellular activation that follow RhoB’s
induction because of multiple types of cellular stress.
Indeed, we observed that there is an increase in RhoB
Figure 6. Simvastatin improves glycemic control. RhoB/, RhoB/, and
RhoB/ animals were injected with simvastatin 2 days before the first STZ
injection and for 14 consecutive days. Simvastatin succeeded in bringing the
level of hyperglycemia down in all groups (dashed lines, animals treated
with simvastatin and STZ; solid lines, animals treated with STZ and vehicle).
Values are the mean  SE. The SE (n  16 to 30) is shown as the error bar.
RhoB/, n 10; RhoB/, n 16; RhoB/, n 11; simvastatin-RhoB/,
/ /n 7; simvastatin-RhoB , n 13; simvastatin-RhoB , n 21. *P 0.05
versus the same genotype injected with simvastatin.expression both in the kidneys of mice that have been
diabetic for 3 months and in pancreatic islets of hyper-
glycemic mice 3 weeks after the last STZ injection.
Several studies have shown different approaches for
protecting  cells from STZ-induced apoptosis, includ-
ing using antioxidants24,25 and recombinant gene ther-
apy.26,27 Our study shows that loss of RhoB protects both
pancreatic  cells from destruction by inhibiting apoptosis
and organs from secondary complications associated with
hyperglycemia. Specifically, we examined nephropathy
and delayed wound healing in STZ-treated animals. Both
diabetic nephropathy and diabetic wound healing have
been related to diabetic microvascular disease. In the
kidney, microvascular damage and leak leads to the ac-
cumulation of extracellular basement membrane, which
exacerbates the failure of filtration in the glomeruli. In
wound healing, angiogenesis and lymphangiogenesis
are rate limiting for healing and clearing of tissue dam-
age. Thus, the additional benefit gained by loss of RhoB
on the microvasculature could participate in the improve-
ment of diabetic complications in RhoB-null animals.
In our experiments, only hyperglycemic animals were
included in the STZ-treated groups. However, we ob-
served that hyperglycemic RhoB/ mice had lower glu-
cose levels than STZ-treated wild-type mice. Conse-
quently, it is difficult to determine whether the improved
complications are because of the lack of RhoB in affected
tissues or simply the more favorable glycemic levels in
the STZ-treated RhoB/ mice. Because we used a con-
stitutive knockout model, it is also difficult to conclude
whether the improvements in wound healing and ne-
phropathy are because of improved glycemic control or
Figure 5. RhoB loss improves wound healing in
hyperglycemic mice. A: There was no difference
in the wound-healing rates of the non–STZ-
treated RhoB/ and RhoB/ animals. When
the same experiment was performed in STZ-
treated RhoB/ and RhoB/ hyperglycemic
mice, the RhoB/ animals showed significantly
delayed wound healing compared with the non–
STZ-treated controls and the hyperglycemic
RhoB/ mice (triangles, solid line). STZ treated
RhoB/ mice healed significantly faster than
their wild-type peers. Values are the mean  SE.
The SE is shown as the error bar. RhoB/, n 
18; RhoB/, n 20; STZ-RhoB/, n 33; and
STZ-RhoB/, n  20. *P  0.05 versus diabetic
RhoB/. B: Histological examination of the
wounds at day 14. No difference was observed
in the wounds of RhoB/ and RhoB/ un-
treated mice. On the other hand, the STZ-treated
RhoB/ mice showed a significant delay in
their wound-healing process when compared
with the STZ-treated RhoB/ mice. The STZ-
treated RhoB/ unhealed wounds showed ex-
tended granulated tissue, edema, significant
scabbing, and lack of a good layer definition. On
the other hand, the wounds of hyperglycemic
RhoB/ mice showed histological features sim-
ilar to those of the untreated mice. C: Represen-
tative image of the wound-healing process
showing the delayed wound healing in RhoB/
hyperglycemic animals.loss of RhoB in the microvasculature of those affected
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specific deletion of RhoB could identify a specific mech-
anism for the milder diabetic complications observed in
the RhoB/ mice. In summary, RhoB presents itself as
an attractive cellular target for diabetic therapy.
Previous studies have used statins to reduce the STZ-
induced hyperglycemia in control animals and in non-
obese diabetic mice.9 Our experiments show that simva-
statin injections reduced the number of animals that
developed hyperglycemia and the average fasting glu-
cose level, regardless of the number of copies of RhoB in
the genome. Therefore, the effect of simvastatin on pro-
tecting the islets is not solely dependent on RhoB.
Rydgren and Sandler28 found that the beneficial effect of
statins in glycemic control after STZ treatment was inde-
pendent of HMG-CoA reductase inhibition in their mod-
els. However, because RhoB function is strongly associ-
ated with prenylation status, we cannot rule out the
possibility that the positive effects of simvastatin in RhoB
wild-type settings are benefited by loss of RhoB preny-
lation. Nevertheless, we propose that RhoB-targeted
therapy could be used as an alternative or in combination
with statins to improve the lives of diabetic patients.
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